US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters
US FDA approves Axsome's drug for Alzheimer's-related agitation Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPWVphYlZWc0RER3F3c09sMXhsQkE4b0lzaXhWM3FYV2lza19mU3Y1WWI4WElZbmxOc3FGUE9UaUN2VmVQYjRuaHJQU0lQS3V5Y2Z5Wk1lVkNGelEyMHMwSXR1YWRWYk9ULV9zTFBvX291RmpHakpodm04MHpfWl9lZlVhVGdiM2tiQ3BWb080NWFrR1VUdUxsb2FmTE5LT2xnSlZrVHotRzY3OHV0d0d2djlUSUVEV3lQeXY5VnBvWWlHUTZZNXd1Yw?oc=5" target="_blank">US FDA approves Axsome's drug for Alzheimer's-related agitation</a> <font color="#6f6f6f">Reuters</font>
The FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for treating agitation in Alzheimer's patients, marking the first non-antipsychotic treatment for this condition.
Axsome Therapeutics announced the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease, a first-in-class treatment targeting NMDA and sigma-1 receptors.
The FDA approved Axsome Therapeutics' drug, Auvelity, to treat agitation in Alzheimer's patients, offering an alternative to antipsychotic drugs.
Axsome Therapeutics received FDA approval for Auvelity to treat Alzheimer's disease agitation, accessing a $1 billion-plus market and offering a clean label compared to competitors.
The FDA approved Axsome Therapeutics' Auvelity for treating agitation in Alzheimer's disease, providing a new option to ease caregiver burden.
Similar Stories
Related coverage based on topic and tags
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug - Reuters
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug Reuters
July 13, 2026 at 08:59 PMBiogen's Alzheimer's drug lowers toxic protein, but results were mixed - Reuters
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed Reuters
July 14, 2026 at 04:17 PMUS FDA approves Vera's kidney disease drug - Reuters
US FDA approves Vera's kidney disease drug Reuters
July 7, 2026 at 05:09 PMUS FDA approves Celcuity's breast cancer drug - Reuters
US FDA approves Celcuity's breast cancer drug Reuters
July 14, 2026 at 10:36 PMUS FDA approves Sanofi's wearable injector form of blood cancer drug - Reuters
US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters
July 10, 2026 at 05:49 PMSouth African regulators issue recall of Ozempic copies - Reuters
South African regulators issue recall of Ozempic copies Reuters
July 9, 2026 at 09:14 PM